Children and adolescents aged 3 to 18 years old with growth hormone deficiency (GHD) should be able receive treatment with Ascendis Pharma's growth hormone Skytrofa, says the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
However, before the drug can marketed, the EU Commission must first ratify the proposal. Still, drugs that have received the CHMP's stamp of approval usually pass through the Commission within a few months, as its final decision is often more of a formality. In Ascendis Pharma's case, this is therefore expected to happen before the end of January.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
New CCO at crisis-hit Lundbeck: "2022 will be a growth year for Lundbeck in all regions"
Jacob Tolstrup will be responsible for renewing sales growth at Lundbeck, having made his way through the ranks.
Coloplast upgrades growth expectations following acquisition
Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.
Demant's surgical division loses president of 13 years
Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.
Hearing aid market in US grew by 37 percent in 2021
Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.
Lundbeck's migraine drug approved in EU
Vyepti has become the first approved intravenous preventative migraine treatment in the region.
Senior Manager, Biostatistics 
Senior Manager/Associate Director Regulatory Affairs 
Senior Key Account Manager 
Design Control Specialist / System Engineer 
Commercial Excellence Lead 
KLIFO is looking for a Director, Business Support for our Glostrup office 
Principal Scientist 
Chemists are wanted for ALK's internal Aircraft Corps 
Associate Director, GMP QA, Biologics/Radiopharmaceuticals 
QA Specialist 
NORDIC Medical Sales Director 
Head of Bioinformatics, Muna Therapeutics 
Senior HR Director, HR Denmark, Ferring 
GxP QA Compliance Manager for Quality Assurance